Scientific Evidence for
RFQMR-FRB Neurological Therapy

63-study meta-analysis (1,342 active participants, 505 controls). rTMS reduced seizure frequency by 30.2%, tDCS by 46.9%. Responder rates (>50% seizure reduction): rTMS 38%, tDCS 49%. No serious adverse events. The most comprehensive analysis of non-invasive electromagnetic therapy in drug-resistant epilepsy.

10-RCT meta-analysis (269 patients). Electromagnetic stimulation (tDCS) reduced monthly seizure frequency by 45.4% at 4 weeks and 39.3% at 8 weeks, with significant reduction in epileptiform discharges. No serious adverse events. Provides the highest level of evidence for seizure-frequency reduction through electromagnetic field modulation.

2026 study identifying glymphatic system dysfunction as a measurable imaging biomarker in DRE. Patients with higher brain waste-clearance indices showed significantly better neuromodulation response — establishing that neurological homeostatic function predicts therapeutic responsiveness and supports patient selection in DRE neuromodulation.

2026 review covering TMS, tES and combined neuromodulation for disorders of consciousness following TBI and hypoxic brain injury. High-frequency rTMS (10–20 Hz) targeting the dorsolateral prefrontal cortex produced significant consciousness score improvements with sustained effects. Adverse events minimal across all modalities.

329-patient multicentre RCT. Electrical stimulation (40 Hz) in acute traumatic coma: 72.5% regained consciousness vs. 56.8% controls (p=0.004). Significantly improved GOSE at 3 and 6 months. Demonstrates electromagnetic stimulation as a safe, effective intervention that measurably increases the proportion of TBI patients who recover consciousness.

Review of TMS and tDCS evidence in mTBI across depression, headache, and cognitive domains. TMS shows promising results for post-concussive depression and headache. Supports electromagnetic neuromodulation as a targeted, non-pharmacological approach to the multi-symptom burden of TBI — applicable to Ardram's patients with hypoxic and traumatic brain injury.

Landmark review by Michael Levin (Tufts University) establishing that endogenous transmembrane voltage potentials (Vmem) serve as instructive patterning cues for large-scale tissue anatomy — not merely passive by-products of cellular metabolism. Spatiotemporal Vmem gradients carry positional information that controls cell differentiation, proliferation, migration and organogenesis. Pharmacological modulation of these gradients in vivo can initiate complex organogenesis, change tissue identity, and trigger whole vertebrate appendage regeneration. Directly establishes the scientific basis for how RFQMR-FRB therapy — by modulating transmembrane voltage — can activate downstream gene expression and tissue repair programs in neurological conditions.

Demonstrates that membrane potential (Vmem) is a direct, pharmacologically manipulable controller of cell proliferation in mesenchymal stem cells — the same progenitor cells implicated in neural tissue repair. Blocking and unblocking the Na/K-ATPase pump (which governs transmembrane electrochemical gradients) directly switches proliferation on and off, establishing Vmem regulation as a fundamental targetable mechanism in regenerative medicine. Provides mechanistic support for how RFQMR-FRB modulation of transmembrane potential activates the regenerative cellular programs observed clinically in neurological patients.

22-study systematic review establishing that electromagnetic fields modulate neuronal ion channels at multiple levels — gating dynamics, ion conductance, membrane concentration, and critically, gene and protein expression. Calcium homeostasis via voltage-gated calcium channels (VGCCs) is the most commonly reported downstream effect. Establishes that neuronal ion channels are the primary transducer converting electromagnetic field exposure into changes in gene expression and protein production — the precise molecular chain that RFQMR-FRB therapy exploits: EMF → ion channel modulation → transmembrane potential change → gene activation → neurological repair.

Traces the precise molecular pathway from electromagnetic field exposure to neurotrophic gene expression: PEMF → L-type voltage-gated calcium channel activation → calcium influx → Erk1/2 phosphorylation → BDNF mRNA upregulation. BDNF (Brain-Derived Neurotrophic Factor) is the single most important protein for neuronal survival, synaptic plasticity, and neuroregeneration. This study maps the exact signalling cascade by which RFQMR-FRB therapy — operating through transmembrane ion channel modulation — drives expression of the proteins most critical to neurological recovery, providing molecular-level validation of the Cytotron mechanism diagram.

Demonstrates in vertebrate embryos — including human embryonic stem cells — that membrane voltage (Vmem) directly governs the transition from undifferentiated to differentiated cell fates via a calcium/mTOR signalling axis. Depolarisation of Vmem elevates intracellular calcium, which suppresses differentiation into ectodermal and myogenic lineages; hyperpolarisation releases cells into differentiated fates. Published in Nature Communications, this establishes transmembrane potential as a master regulator of cell fate commitment — providing mechanistic grounding for why RFQMR-FRB modulation of Vmem can redirect neural progenitor cells toward regenerative differentiation programs.

242-citation study establishing that endogenous transmembrane hyperpolarisation is a functional determinant of mesenchymal stem cell differentiation. Pharmacological depolarisation of Vmem suppresses differentiation; hyperpolarising reagents upregulate osteogenic gene markers. Demonstrates that Vmem is a tractable, modifiable control point for directing stem cell fate — directly supporting the rationale that RFQMR-FRB electromagnetic modulation of transmembrane potential can activate regenerative stem cell programs in neural tissue.

Annual Review of Biomedical Engineering overview of developmental bioelectricity from the world's leading laboratory in this field. Establishes that endogenous bioelectric signaling networks — driven by ion channel and pump activity across cell membranes — regulate pattern formation, tissue growth and regeneration across species. Presents molecular tools for exploiting voltage gradients therapeutically and proposes that cracking the bioelectric code will drive transformative advances in regenerative medicine. The core theoretical framework underpinning why transmembrane potential modulation via RFQMR-FRB translates into measurable anatomical repair.

Seminal study in mammalian neurons establishing the precise cascade: membrane depolarisation → voltage-sensitive Ca²⁺ channel activation → CaMK/calcineurin activation → induction of genes encoding BDNF, NMDA receptor subunits, GABA receptor subunits, and MEF2A — all directly governing neuronal maturation, synaptic development and dendritic morphogenesis. Demonstrates that transmembrane potential changes are not a downstream consequence but an upstream regulator of the neuronal gene expression programs critical to brain development and repair.

2025 study demonstrating that pulsed electromagnetic fields (PEMFs) — operating on the same physical principles as RFQMR-FRB — rescue oxidatively stressed neurons modelling Alzheimer's disease by: restoring mitochondrial membrane potential, reducing reactive oxygen species, inhibiting apoptosis (caspase-3), and specifically upregulating the CREB phosphorylation → BDNF expression pathway. Provides direct mechanistic evidence that electromagnetic field therapy preserves and restores the transmembrane potential-driven CREB/BDNF signalling cascade in neurodegeneration — exactly the pathway RFQMR-FRB activates to promote neuroprotection and neuroplasticity.